Physician profile
Tomas Holmlund
NPI 1770644528
$42,385.53
in general payments reported to CMS, 2019-2025
61 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $9,794 · 2021: $12K · 2022: $1,867 · 2023: $435 · 2024: $426 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,864.78 | 2019-2021 | |
| Tanabe Pharma America, INC. | $11,353.86 | 2019-2025 | Radicava |
| Alexion Pharmaceuticals, INC. | $7,674.43 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $1,002.71 | 2019-2024 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $832.23 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $590.56 | 2019-2022 | |
| Argenx US, INC. | $521.53 | 2022-2023 | Vyvgart |
| Alnylam Pharmaceuticals INC. | $326.32 | 2019-2024 | Onpattro |
| Neurocrine Biosciences, INC. | $271.05 | 2019-2025 | Ingrezza |
| Adamas Pharmaceuticals, INC. | $262.27 | 2020-2021 | |
| Ucb, INC. | $241.79 | 2020-2025 | Rystiggo, Briviact |
| Acadia Pharmaceuticals INC | $203.80 | 2019-2022 | |
| Abbvie INC. | $198.20 | 2021-2025 | |
| Merz North America, INC. | $187.68 | 2019-2020 | |
| Horizon Therapeutics Plc | $180.59 | 2021 |
Show all 59 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$403,081.62 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Holmlund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.